{"id":"hx575-epoetin-alfa-sandoz","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events (venous thromboembolism, stroke)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pure red cell aplasia (rare)"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for red blood cell production. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation, increasing hemoglobin and hematocrit levels. HX575 is a biosimilar formulation developed by Sandoz intended to be therapeutically equivalent to the reference epoetin alfa product.","oneSentence":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:33.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing major surgery"}]},"trialDetails":[{"nctId":"NCT01576341","phase":"PHASE3","title":"HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-04","conditions":"Chronic Kidney Disease","enrollment":417}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®"],"phase":"phase_3","status":"active","brandName":"HX575 epoetin alfa (Sandoz)","genericName":"HX575 epoetin alfa (Sandoz)","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}